Farmazolin N (xylometazoline hydrochloride) nasal spray 1 mg/ml. 15 ml.

Description

Farmazolin N Storage
active substance: xylometazoline hydrochloride;

1 ml of the drug contains xylometazoline hydrochloride in terms of 100% of the substance 1 mg;

excipients: benzalkonium chloride; sodium chloride; sodium dihydrogen phosphate, dihydrate; sodium hydrogen phosphate, dodecahydrate; water for injections.

Farmazolin N Dosage form
Nasal spray.

Basic physical and chemical properties: transparent colorless liquid.

Farmazolin N Pharmacotherapeutic group
Anti-edema and other drugs for topical use in diseases of the nasal cavity. Sympathomimetics, simple drugs. ATX code R01A A07.

Pharmacological properties

Pharmacodynamics.

Xylometazoline is a sympathomimetic agent that acts on α-adrenergic receptors.

Farmazolin® H causes narrowing of nasal blood vessels, reducing swelling and redness of the nasal mucosa, its paranasal sinuses and, thus, improving nasal breathing with nasal and paranasal sinuses.

The effect of the drug begins a few minutes after application and lasts up to 12 hours (for example, overnight).

The drug is well tolerated, including patients with sensitive mucous membranes. The drug does not reduce mucociliary function. Farmazolin® H has a balanced pH value within the limits inherent in the nasal cavity.

In vitro studies have shown that xylometazoline reduces the infectious activity of human rhinovirus associated with the common cold.

Pharmacokinetics.

When applied topically, the concentrations of xylometazoline in blood plasma are so small that they cannot be determined by modern analytical methods.

Indication
Symptomatic treatment of nasal congestion with colds, hay fever, allergic rhinitis, sinusitis.

To facilitate the outflow of secretions in diseases of the paranasal sinuses.

Adjuvant therapy in cases of otitis media (to eliminate mucosal edema).

To facilitate rhinoscopy.

Contraindication
Hypersensitivity to the components of the drug; acute coronary heart disease, coronary asthma, hyperthyroidism, angle-closure glaucoma, dry rhinitis (rhinitis sicca) or atrophic rhinitis, surgery to expose the dura mater or transphenoidal hypophysectomy. Concomitant treatment with MAO inhibitors and for 2 weeks after discontinuation.

Interaction with other medicinal products and other forms of interaction
Monoamine oxidase inhibitors (MAO inhibitors): xylometazoline may potentiate the action of monoamine oxidase inhibitors, which may cause hypertensive crisis. Xylometazoline is not recommended for patients who have been taking or have been taking MAO inhibitors for the past two weeks.

Tri- and tetracyclic antidepressants: concomitant use of tri- or tetracyclic antidepressants and sympathomimetic drugs may increase the sympathomimetic effect of xylometazoline, so the simultaneous use of such drugs is not recommended.

When used in combination with β-blockers, it can cause bronchospasm or lower blood pressure.

Features of application
The drug should not be used for more than 10 consecutive days. Prolonged or excessive use may lead to recurrence of nasal congestion and / or atrophy of the nasal mucosa.

Do not exceed the recommended dose, especially in the treatment of children and the elderly.

The drug should be used with caution in patients with cardiovascular disease, high blood pressure, diabetes, prostate hypertrophy, pheochromocytoma due to the possible systemic sympathomimetic effect. The drug, like other sympathomimetics, should be used with caution in patients who have severe reactions to adrenergic drugs, manifested as sleep disturbances, dizziness, tremors, cardiac arrhythmia, increased blood pressure. The drug contains benzalkonium chloride, which may irritate the skin and mucous membranes.